Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease
By
Tracy A Cole,
Hien Zhao,
Timothy J Collier,
Ivette Sandoval,
Caryl E. Sortwell,
Kathy Steece-Collier,
Brian F Daley,
Alix Booms,
Jack Lipton,
Mackenzie Welch,
Melissa Berman,
Luke Jandreski,
Danielle Graham,
Andreas Weihofen,
Stephanie Celano,
Emily Schulz,
Allyson Cole-Strauss,
Esteban Luna,
Duc Quach,
Apoorva Mohan,
C. Frank Bennett,
Eric E Swayze,
Holly B Kordasiewicz,
Kelvin Luk,
Katrina L Paumier
Posted 04 Nov 2019
bioRxiv DOI: 10.1101/830554
Parkinson's disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding alpha-synuclein protein (aSyn), either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent pre-formed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the non-human primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that by inhibiting production of aSyn it may be possible to reverse established pathology and thus supports the development of SNCA ASOs as a potentially disease modifying therapy for PD and related synucleinopathies.
Download data
- Downloaded 2,071 times
- Download rankings, all-time:
- Site-wide: 11,259
- In neuroscience: 1,065
- Year to date:
- Site-wide: 46,782
- Since beginning of last month:
- Site-wide: 60,753
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!